Individual differences of plasma proteins and factors in fresh frozen plasma from Chinese regional blood donors

  • Liguo Zhu
  • Changqing LiEmail author
  • Deqing WangEmail author


Currently, single fresh frozen plasma (FFP) for clinical use is derived from individual blood donors. The objective of this study is to investigate the differences in single FFP units to make related strategies for improving FFP transfusion efficacy. 120 units of single FFP were selected randomly from Chinese PLA Clinical Blood Transfusion Center in Beijing, China. Single FFP samples were thawed in 37 °C water bath and were assessed immediately for total protein (TP), albumin (Alb), fibrinogen (Fg), factor V (FV), factor VIII (FVIII), antithrombin-III (AT-III) and protein C (PC). Multiple comparisons were employed to analysis the differences. The quality levels of 120 single FFP units showed wider ranges and presented normal distribution. Fg, FV and PC showed larger fluctuation range but TP, Alb, FVIII and AT-III showed smaller. The mean level of TP was 56.07 g/L and FVIII was 0.62 IU/mL. There were no significant differences to genders in single FFP units. FFP from younger people with 18–30 years old showed a trend towards reduced activity of coagulation factors, especially FV and FVIII. TP and Alb levels in FFP with type O were significantly higher than that in non-O type, but FVIII, AT-III and PC levels were lower in type O than that in non-O type. In a word, the whole quality of single FFP units from Chinese regional donors was acceptable, except FVIII. There were great differences of plasma proteins and factors in single FFP units, age and ABO blood type were main influence factors.


Individual differences Fresh frozen plasma Plasma proteins and factors Blood donors Chinese 







Fresh frozen plasma




Factor V


Factor VIII


Protein C


Total protein



We thank experimental supports of Fengyan Fan, Liping Sun, Dongqing Zhang from Department of Blood Transfusion, Chinese PLA General Hospital and Ping Di from Department of Clinical Laboratory, Chinese PLA General Hospital.


This study was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS, No. 2017-I2M-3-021), the Sichuan Provincial Science and Technology Project (No. 2017JY0064), and the Military Major Special Project (AWS11J007-08).

Compliance with ethical standards

Conflict of interest

The authors have disclosed no conflicts of interest.

Ethical approval

The Institutional Ethics Committee of CPGH approved this study.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    O’Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM (2004) Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126(1):11–28CrossRefGoogle Scholar
  2. 2.
    Puetz J (2013) Fresh frozen plasma: the most commonly prescribed hemostatic agent. J Thromb Haemost 11(10):1794–1799PubMedGoogle Scholar
  3. 3.
    National Health and Family Planning Commission of the People’s Republic of China (2000) The Technical Criterion of Clinical Blood TransfusionGoogle Scholar
  4. 4.
    European Parliament. Commission directive 2004/33/EC. Official Journal of the European Union 2004, 2004Google Scholar
  5. 5.
    National Health and Family Planning Commission of the People’s Republic of China (2012) Quality requirements for whole blood and blood componentsGoogle Scholar
  6. 6.
    Madla W, Alt T, Jungk H, Bux J (2012) Fresh frozen plasma quality: relation to age and gender of blood donors. Vox Sang 102(2):116–124CrossRefGoogle Scholar
  7. 7.
    Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J (1985) Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population—II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost 54(3):721–723CrossRefGoogle Scholar
  8. 8.
    Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J (1985) Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 54(2):475–479PubMedGoogle Scholar
  9. 9.
    Folsom AR, Conlan MG, Davis CE, Wu KK (1992) Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol 2(4):481–494CrossRefGoogle Scholar
  10. 10.
    Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H (1997) Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 97(4):775–784CrossRefGoogle Scholar
  11. 11.
    Mari D, Coppola R, Provenzano R (2008) Hemostasis factors and aging. Exp Gerontol 43(2):66–73CrossRefGoogle Scholar
  12. 12.
    Wang Z, Liu H, Dou M, Du X, Hu J, Su N, Wang Y, Zhang R, Li C.The quality changes in fresh frozen plasma of the blood donors at high altitude. PLoS ONE 2017 12(4):e0176390Google Scholar
  13. 13.
    Wang ZK, Dou MM, Du X, Ma L, Sun P, Cao HJ et al (2017) Influences of ABO blood group, age and gender on plasma coagulation factor VIII, fibrinogen, von Willebrand factor and ADAMTS13 levels in a Chinese population. PeerJ 5:e3156CrossRefGoogle Scholar
  14. 14.
    Favaloro EJ, Soltani S, Mc Donald J, Grezchnik E, Easton L, Favaloro JW (2005) Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder. Am J Clin Pathol 124(6):910–917CrossRefGoogle Scholar
  15. 15.
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA (1999) Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999 82(5):1456–1461CrossRefGoogle Scholar
  16. 16.
    Hamilton PJ, Allardyce M, Ogston D, Dawson AA, Douglas AS (1974) The effect of age upon the coagulation system. J Clin Pathol 27:980–982CrossRefGoogle Scholar
  17. 17.
    Albánez S, Ogiwara K, Michels A, Hopman W, Grabell J, James P, Lillicrap D (2016) Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost 14(5):953–963CrossRefGoogle Scholar
  18. 18.
    Rios DRA, Fernandes AP, Figueiredo RC, Guimaraes DAM, Ferreira CN, Silva E, Carvalho ACS, Gomes MG, Dusse KB (2012) LMS. Relationship between ABO blood groups and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing hemodialysis. J Thromb Thrombolysis 33:416–421CrossRefGoogle Scholar
  19. 19.
    Solheim BG, Chetty R, Flesland O (2008) Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Hematol 15(6):612–617CrossRefGoogle Scholar
  20. 20.
    Heger A, Brandstätter H, Prager B, Brainovic J, Cortes R, Römisch J (2015) Universal pooled plasma (Uniplas(®)) does not induce complement-mediated hemolysis of human red blood cells in vitro. Transfus Apher Sci 52(1):128–135CrossRefGoogle Scholar
  21. 21.
    Wang S, Zhou W, Zhuang Y, Zhang D, Li H, Wang D (2012) Study on preparation of universal plasma in Chinese Han population. Transfus Apher Sci 47(2):167–170CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Blood TransfusionChinese Academy of Medical Sciences and Peking Union Medical CollegeChengduChina
  2. 2.Department of Blood TransfusionChinese PLA General HospitalBeijingChina

Personalised recommendations